KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study.

Riffat Mehboob, Imran Shahid, Abdullah R Alzahrani, Shimaa Mohammad Yousof, Hafsa Adnan, Samar N Ekram, Ahmad Alwazzan, Hisham Nasief, Khalid A Khadawardi

Health Sci Rep 9(1) e71744

PMID41561887
PMCIDPMC12813412
DOI10.1002/hsr2.71744
发表日期2026-01-21
摘要

摘要

BACKGROUND AND AIMS: Primary dysmenorrhea is a prevalent condition that causes significant menstrual pain and discomfort, impacting many women's daily activities. The Substance P/NK1 receptor (SP/NK1R) pathway has been linked to the pain mechanisms underlying dysmenorrhea, yet its potential as a therapeutic target remains inadequately explored. This study aimed to evaluate the therapeutic potential of NK1R antagonists, specifically dexamethasone and aprepitant, in alleviating the symptoms of primary dysmenorrhea. METHODS: A randomized controlled trial was conducted from March 2024 to December 2024 using a convenience sampling technique. Forty female participants were divided into three phases: Phase 1 (pre-medication), Phase 2 (NSAIDs), and Phase 3 (dexamethasone + aprepitant). Ten control females without dysmenorrhea were also recruited. The study lasted for three menstrual cycles, with assessments of SP/NK1R levels, visual analogue scores (VAS), and pictorial blood loss. Data were analyzed using Two-way ANOVA with repeated measures. RESULTS: The mean age of participants was 25.1 ± 7.6 years, and BMI was 20.47 ± 3.61 kg/m². SP/NK1R levels were significantly elevated in Phase 1 compared to controls. NK1R levels decreased significantly from 15.4 ng/mL in Phase 1 to 8.42 ng/mL in Phase 3. VAS scores decreased by 4.79 units. A linear mixed-effects model revealed significant reductions in NK1R levels in Phase 2 versus Phase 1 (p < 0.001) and Phase 3 versus Phase 1 (p = 0.006). VAS scores improved significantly in Phase 3 compared to Phase 2 (p = 0.0001 for SP and p = 0.0028 for NK1R). Heavy period patients had higher SP levels. Both SP and NK1R levels decreased across phases for normal and heavy period patients. CONCLUSION: This pilot study suggests that NK1R antagonists (dexamethasone and aprepitant) may reduce discomfort in dysmenorrhea. Further research with a larger sample size and control for intra-individual hormone levels is needed.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。